Cochrane · systematic review · CD011033
Pharmacological treatment for Buerger's disease
Cacione, DG, Macedo, CR, do Carmo Novaes, F, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
10
No studies
2
Included studies
NR
No studies 2 · 16.7%Ungraded 0 · 0%Very low 3 · 25%Low 1 · 8.3%Moderate 6 · 50%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version only(Oral or intravenous) prostanoid versus aspirin treatment for Buerger's disease
Population: patients with Buerger's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Ulcer healing (Oral or intravenous) prostanoid vs aspirin treatment | RR 2.65 [1.15, 6.11] | 1 study · 98 participants | Moderate Downgraded: imprecision |
Complete relief of rest pain (Oral or intravenous) prostanoid vs aspirin treatment | RR 2.28 [1.48, 3.52] | 1 study · 133 participants | Moderate Downgraded: imprecision |
Rate of amputation (Oral or intravenous) prostanoid vs aspirin treatment | RR 0.32 [0.09, 1.15] | 1 study · 95 participants | Moderate Downgraded: imprecision |
Intravenous prostacyclin analogue versus intravenous prostaglandin analogue for treatment of Buerger's disease
Population: patients with Buerger's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Ulcer healing Intravenous prostacyclin analogue vs intravenous prostaglandin analogue | RR 1.13 [0.76, 1.69] | 2 studies · 89 participants | Very low Downgraded: imprecision |
Complete relief of pain Intravenous prostacyclin analogue vs intravenous prostaglandin analogue | RR 1.57 [0.72, 3.44] | 1 study · 38 participants | Low Downgraded: imprecision |
Rate of amputation Intravenous prostacyclin analogue vs intravenous prostaglandin analogue | no estimate extracted | NR | No studies |
(Oral or intravenous) prostanoid versus placebo for treatment of Buerger's disease
Population: patients with Buerger's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Ulcer healing (Oral or intravenous) prostanoid vs placebo | RR 1.11 [0.54, 2.29] | 1 study · 133 participants | Moderate Downgraded: imprecision |
Complete relief of rest pain (Oral or intravenous) prostanoid vs placebo | RR 1.14 [0.79, 1.63] | 1 study · 207 participants | Moderate Downgraded: imprecision |
Rate of amputation (Oral or intravenous) prostanoid vs placebo | RR 0.54 [0.19, 1.56] | 1 study · 209 participants | Moderate Downgraded: imprecision |
Any pharmacological agent versus placebo or any other pharmacological agent for treatment of Buerger's disease
Population: patients with Buerger's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Ulcer healing Any pharmacological agent vs placebo or any other pharmacological agent | no estimate extracted | NR | No studies |
Pain VAS. Scale from: 0 to 10; higher score = more pain Any pharmacological agent vs placebo or any other pharmacological agent | no estimate extracted | 1 study · 30 participants | Very low |
Change in rate of amputation (Difference in number of amputations at start of treatment) Any pharmacological agent vs placebo or any other pharmacological agent | no estimate extracted | 1 study · 30 participants | Very low |
Summary of findings: Oral prostacyclin analogue (iloprost) versus placebo
Population: patients with Buerger's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Ulcer healing (200 mcg) Summary of findings: Oral prostacyclin analogue (iloprost) vs placebo | RR 1.11 [0.54, 2.29] | 1 study · 133 participants | Moderate Downgraded: imprecision, inconsistency |
Ulcer healing (400 mcg) Summary of findings: Oral prostacyclin analogue (iloprost) vs placebo | RR 0.9 [0.42, 1.93] | 1 study · 135 participants | Moderate Downgraded: imprecision, inconsistency |
Ulcer healing (200 mcg) Summary of findings: Oral prostacyclin analogue (iloprost) vs placebo | RR 1.19 [0.82, 1.73] | 1 study · 133 participants | Moderate Downgraded: imprecision, inconsistency |
Ulcer healing (400 mcg) Summary of findings: Oral prostacyclin analogue (iloprost) vs placebo | RR 1 [0.67, 1.5] | 1 study · 135 participants | Moderate Downgraded: imprecision, inconsistency |
Complete relief of rest pain (200 mcg) Summary of findings: Oral prostacyclin analogue (iloprost) vs placebo | RR 1.14 [0.79, 1.63] | 1 study · 207 participants | Moderate Downgraded: imprecision, inconsistency |
Complete relief of rest pain (400 mcg) Summary of findings: Oral prostacyclin analogue (iloprost) vs placebo | RR 1.11 [0.77, 1.59] | 1 study · 210 participants | Moderate Downgraded: imprecision, inconsistency |
Complete relief of rest pain (200 mcg) Summary of findings: Oral prostacyclin analogue (iloprost) vs placebo | RR 1.28 [1, 1.64] | 1 study · 207 participants | Low Downgraded: imprecision, inconsistency |
Complete relief of rest pain (400 mcg) Summary of findings: Oral prostacyclin analogue (iloprost) vs placebo | RR 1 [0.76, 1.32] | 1 study · 210 participants | Moderate Downgraded: imprecision, inconsistency |
Rate of amputation (200 mcg) Summary of findings: Oral prostacyclin analogue (iloprost) vs placebo | RR 0.54 [0.19, 1.56] | 1 study · 209 participants | Moderate Downgraded: imprecision, inconsistency |
Rate of amputation (400 mcg) Summary of findings: Oral prostacyclin analogue (iloprost) vs placebo | RR 0.42 [0.13, 1.31] | 1 study · 213 participants | Moderate Downgraded: imprecision, inconsistency |
Summary of findings: Intravenous prostacyclin analogue (iloprost) versus oral aspirin
Population: patients with Buerger's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Ulcer healing Summary of findings: Intravenous prostacyclin analogue (iloprost) vs oral aspirin | RR 2.65 [1.15, 6.11] | 1 study · 98 participants | Moderate Downgraded: imprecision |
Ulcer healing Summary of findings: Intravenous prostacyclin analogue (iloprost) vs oral aspirin | RR 4.03 [1.24, 13.1] | 1 study · 95 participants | Moderate Downgraded: imprecision |
Complete relief of rest pain Summary of findings: Intravenous prostacyclin analogue (iloprost) vs oral aspirin | RR 2.28 [1.48, 3.52] | 1 study · 133 participants | Moderate Downgraded: imprecision |
Rate of amputation Summary of findings: Intravenous prostacyclin analogue (iloprost) vs oral aspirin | RR 0.32 [0.09, 1.15] | 1 study · 95 participants | Moderate Downgraded: imprecision |
Summary of findings: Intravenous prostacyclin analogue versus intravenous prostaglandin analogue
Population: patients with Buerger's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Ulcer healing Summary of findings: Intravenous prostacyclin analogue vs intravenous prostaglandin analogue | RR 1.13 [0.76, 1.69] | 2 studies · 89 participants | Very low Downgraded: imprecision |
Complete relief of pain Summary of findings: Intravenous prostacyclin analogue vs intravenous prostaglandin analogue | RR 1.57 [0.72, 3.44] | 1 study · 38 participants | Low Downgraded: imprecision |
Rate of amputation Summary of findings: Intravenous prostacyclin analogue vs intravenous prostaglandin analogue | no estimate extracted | NR | No studies |
Summary of findings: Folic acid versus placebo
Population: patients with Buerger's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Ulcer healing Summary of findings: Folic acid vs placebo | no estimate extracted | NR | No studies |
Pain (0 month) VAS. Scale from: 0 to 10; higher score = more pain Summary of findings: Folic acid vs placebo | no estimate extracted | 1 study · 30 participants | Very low |
Pain (2 months) VAS. Scale from: 0 to 10; higher score = more pain Summary of findings: Folic acid vs placebo | no estimate extracted | 1 study · 30 participants | Very low |
Pain (6 months) VAS. Scale from: 0 to 10; higher score = more pain Summary of findings: Folic acid vs placebo | no estimate extracted | 1 study · 30 participants | Very low |
Change in rate of amputation (2 months) (Difference in number of amputations at start of treatment) Summary of findings: Folic acid vs placebo | no estimate extracted | 1 study · 30 participants | Very low |
Change in rate of amputation (6 months) (Difference in number of amputations at start of treatment) Summary of findings: Folic acid vs placebo | no estimate extracted | 1 study · 30 participants | Very low |
Summary of findings: Oral prostacyclin analogue (iloprost) versus placebo
Population: patients with Buerger's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Ulcer healing (200 mcg) Summary of findings: Oral prostacyclin analogue (iloprost) vs placebo | RR 1.11 [0.54, 2.29] | 1 study · 133 participants | Moderate Downgraded: imprecision, inconsistency |
Ulcer healing (400 mcg) Summary of findings: Oral prostacyclin analogue (iloprost) vs placebo | RR 0.9 [0.42, 1.93] | 1 study · 135 participants | Moderate Downgraded: imprecision, inconsistency |
Ulcer healing (200 mcg) Summary of findings: Oral prostacyclin analogue (iloprost) vs placebo | RR 1.19 [0.82, 1.73] | 1 study · 133 participants | Moderate Downgraded: imprecision, inconsistency |
Ulcer healing (400 mcg) Summary of findings: Oral prostacyclin analogue (iloprost) vs placebo | RR 1 [0.67, 1.5] | 1 study · 135 participants | Moderate Downgraded: imprecision, inconsistency |
Complete relief of rest pain (200 mcg) Summary of findings: Oral prostacyclin analogue (iloprost) vs placebo | RR 1.14 [0.79, 1.63] | 1 study · 207 participants | Moderate Downgraded: imprecision, inconsistency |
Complete relief of rest pain (400 mcg) Summary of findings: Oral prostacyclin analogue (iloprost) vs placebo | RR 1.11 [0.77, 1.59] | 1 study · 210 participants | Moderate Downgraded: imprecision, inconsistency |
Complete relief of rest pain (200 mcg) Summary of findings: Oral prostacyclin analogue (iloprost) vs placebo | RR 1.28 [1, 1.64] | 1 study · 207 participants | Low Downgraded: imprecision, inconsistency |
Complete relief of rest pain (400 mcg) Summary of findings: Oral prostacyclin analogue (iloprost) vs placebo | RR 1 [0.76, 1.32] | 1 study · 210 participants | Moderate Downgraded: imprecision, inconsistency |
Rate of amputation (200 mcg) Summary of findings: Oral prostacyclin analogue (iloprost) vs placebo | RR 0.54 [0.19, 1.56] | 1 study · 209 participants | Moderate Downgraded: imprecision, inconsistency |
Rate of amputation (400 mcg) Summary of findings: Oral prostacyclin analogue (iloprost) vs placebo | RR 0.42 [0.13, 1.31] | 1 study · 213 participants | Moderate Downgraded: imprecision, inconsistency |
Summary of findings: Intravenous prostacyclin analogue (iloprost) versus oral aspirin
Population: patients with Buerger's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Ulcer healing Summary of findings: Intravenous prostacyclin analogue (iloprost) vs oral aspirin | RR 2.65 [1.15, 6.11] | 1 study · 98 participants | Moderate Downgraded: imprecision |
Ulcer healing Summary of findings: Intravenous prostacyclin analogue (iloprost) vs oral aspirin | RR 4.03 [1.24, 13.1] | 1 study · 95 participants | Moderate Downgraded: imprecision |
Complete relief of rest pain Summary of findings: Intravenous prostacyclin analogue (iloprost) vs oral aspirin | RR 2.28 [1.48, 3.52] | 1 study · 133 participants | Moderate Downgraded: imprecision |
Rate of amputation Summary of findings: Intravenous prostacyclin analogue (iloprost) vs oral aspirin | RR 0.32 [0.09, 1.15] | 1 study · 95 participants | Moderate Downgraded: imprecision |
Summary of findings: Intravenous prostacyclin analogue versus intravenous prostaglandin analogue
Population: patients with Buerger's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Ulcer healing Summary of findings: Intravenous prostacyclin analogue vs intravenous prostaglandin analogue | RR 1.13 [0.76, 1.69] | 2 studies · 89 participants | Very low Downgraded: imprecision |
Complete relief of pain Summary of findings: Intravenous prostacyclin analogue vs intravenous prostaglandin analogue | RR 1.57 [0.72, 3.44] | 1 study · 38 participants | Low Downgraded: imprecision |
Rate of amputation Summary of findings: Intravenous prostacyclin analogue vs intravenous prostaglandin analogue | no estimate extracted | NR | No studies |
Summary of findings: Folic acid versus placebo
Population: patients with Buerger's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Ulcer healing Summary of findings: Folic acid vs placebo | no estimate extracted | NR | No studies |
Pain (0 month) VAS. Scale from: 0 to 10; higher score = more pain Summary of findings: Folic acid vs placebo | no estimate extracted | 1 study · 30 participants | Very low |
Pain (2 months) VAS. Scale from: 0 to 10; higher score = more pain Summary of findings: Folic acid vs placebo | no estimate extracted | 1 study · 30 participants | Very low |
Pain (6 months) VAS. Scale from: 0 to 10; higher score = more pain Summary of findings: Folic acid vs placebo | no estimate extracted | 1 study · 30 participants | Very low |
Change in rate of amputation (2 months) (Difference in number of amputations at start of treatment) Summary of findings: Folic acid vs placebo | no estimate extracted | 1 study · 30 participants | Very low |
Change in rate of amputation (6 months) (Difference in number of amputations at start of treatment) Summary of findings: Folic acid vs placebo | no estimate extracted | 1 study · 30 participants | Very low |